Skip to content
GEn1E Lifesciences logo

GEn1E Lifesciences

GEn1E Lifesciences is a YC Summer 2019 (S19) company. Based in Palo Alto, CA, USA.

  • Artificial Intelligence
  • Biotech
  • Healthcare
  • Drug discovery

About GEn1E Lifesciences

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

GEn1E Lifesciences builds an AI-driven drug development platform to discover and advance first-in-class immunomodulatory therapies for rare and inflammatory diseases that currently have no effective treatments. The platform targets kinase signaling pathways, specifically p38α:MK2 and ERK 1/2, to create selective modulators that avoid the off-target immunosuppressive effects of earlier kinase inhibitors. Its lead candidate, GEn-1124, is in Phase 2 trials for ARDS, with additional programs targeting Duchenne Muscular Dystrophy and other rare chronic conditions.

Go-to-market

GEn1E Lifesciences advances its own proprietary pipeline through clinical stages, operating as an internal drug developer rather than licensing or selling platform access, with regulatory designations such as FDA Orphan Drug and Rare Pediatric Disease status supporting its path to market.

From the Y Combinator listing

How GEn1E Lifesciences describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

AI platform accelerating therapies for rare & inflammatory diseases.

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Palo Alto, CA, USA
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works